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A b s t r a c t
Background: Beyond lipid-lowering effects, early statin treatment has beneficial effects on prognosis after acute coronary 
syndrome. Infarct-related artery (IRA) patency before percutaneous coronary intervention (PCI) is known to be a strong pre-
dictor of improved clinical outcome. 
Aim: We aimed to investigate the effects of chronic statin treatment before admission on IRA patency after myocardial infarction.
Methods: In this study, 938 ST elevation myocardial infarction (STEMI) patients admitted to the hospital within the first 12 h 
of symptom onset were prospectively enrolled (male, n = 682; female, n = 256; mean age 58.6 ± 12.4 years). All patients 
underwent emergent primary PCI. Patients were divided into two groups based upon angiographic IRA patency. Impaired IRA 
patency was defined as Thrombolysis In Myocardial Infarction (TIMI) grade 0 and 1 flow (non-patent IRA group). Angiographic 
IRA patency was defined as TIMI 2 and 3 flow (patent IRA group). 
Results: Previous statin usage was more frequent in the patent IRA group (n = 138; 71.9%), than in the non-patent IRA 
group (n = 110; 14.7%; p < 0.001). Pre-PCI IRA patency was independently associated with body mass index (odds ra-
tio [OR] = 1.087, 95% confidence interval [CI] 1.005–1.176, p < 0.001), previous chronic statin use (OR 0.065, 95% CI 
0.043–0.098, p = 0.039), ejection fraction (OR 1.041, 95% CI 1.018–1.064, p < 0.001), and SYNTAX score (OR 0.927, 95% 
CI 0.899–0.957, p < 0.001) in multivariate logistic regression analysis. 
Conclusions: Chronic pre-treatment with statins is a significant predictor of the IRA patency in patients with STEMI.
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INTRODUCTION
Early restoration of coronary flow in infarct-related artery (IRA) 
improves ventricular performance and decreases mortality in 
patients with ST elevation myocardial infarction (STEMI) [1]. 
The Thrombolysis In Myocardial Infarction (TIMI) flow grade 
score is a scoring method for assessing coronary blood flow 
[2]. Basal TIMI flow in IRA is crucial for patients with STEMI 
undergoing primary percutaneous coronary intervention (PCI). 
Patients with a patent IRA have lower rates of heart failure and 
cardiogenic shock, improved early and late ejection fraction, 
and reduced short- and long-term mortality [1]. Moreover, 
pre-PCI patency of IRA in patients with STEMI is a major 
determinant of post-PCI TIMI 3 flow, which is associated with 
improved clinical outcome [3].
Previous large clinical trials have demonstrated that statins 
reduce mortality and morbidity associated with cardiovascular 
disease, especially the incidence of myocardial infarction (MI) [4]. 
It was assumed that by lowering serum cholesterol levels, 
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statins cause regression and/or stabilisation of the atheroscle-
rotic plaque [5]. In addition to their potent effect on serum 
lipid levels, statins influence several other cellular pathways, 
including inflammatory, oxidative, and thrombotic processes 
[6]. Statins have also an effect on endothelial function and 
nitric oxide production, independent of changes in serum 
low-density lipoprotein cholesterol (LDL-C) levels [6]. 
We hypothesised that the above-mentioned “pleiotropic” 
effects could contribute to pre-PCI IRA patency in patients 
with STEMI. Furthermore, statins are positively effective on 
post-PCI IRA patency [7, 8]. However, it is unclear whether 
previous chronic statin use affects the pre-PCI IRA patency 
in patients with STEMI. Therefore, we aimed to investigate 
the effects of chronic statin treatment before admission on 
the IRA patency after MI.
METHODS
Study population
In this study, 938 STEMI patients within 12 h of symptom 
onset, in whom primary PCI was performed in our cardiology 
clinic between June 2016 and February 2017, were prospec-
tively included (male, n = 682; female, n = 256; mean age 
58.6 ± 12.4 years). Pretreatment with aspirin, clopidogrel, 
and heparin was administered at the catheter laboratory. 
Urgent diagnostic angiography was followed by primary PCI 
using standard techniques; femoral approach was used. Radial 
approach was not used because of lack of operator expertise 
and technical equipment. STEMI was defined as: typical chest 
pain > 30 min duration with ST elevation > 1 mm in at least 
two consecutive leads on the electrocardiogram or new onset 
left bundle branch block. Glycoprotein IIa/IIIb antagonists 
were used only in case of no reflow phenomenon and high 
thrombus burden after primary PCI, as suggested by the latest 
STEMI guidelines.
Those with a recent history of MI, PCI, coronary artery 
bypass graft, infectious or inflammatory disease, severe liver 
or renal disease, malignancy, or haematological disorders 
were excluded from our study. STEMI was the first clinical 
manifestation of clinically significant cardiovascular disease 
in our study population. All patients were free from any clini-
cally significant peripheral arterial disease, heart failure, or 
stroke. Statins were exclusively used for primary prevention. 
Hyperlipidaemia was the main indication in all patients using 
statin therapy. Atorvastatin and rosuvastatin were used by the 
patients for hyperlipidaemia. 
Patients who presented later than 12 h after the onset 
of symptoms were not included. The study was conducted 
according to the recommendations set forth by the Declara-
tion of Helsinki on Biomedical Research Involving Human 
Subjects. The Institutional Ethics Committee approved the 
study protocol, and each participant provided written, in-
formed consent. 
Baseline characteristics of patients with STEMI were 
recorded, such as age, gender, body mass index, smoking at 
admission, history of hyperlipidaemia, hypertension, diabetes, 
family history of cardiovascular disease, previous medications 
(statins, angiotensin converting enzyme [ACE] inhibitors, an-
giotensin receptor blockers, beta-blockers, oral antidiabetic 
drugs, acetylsalicylic acid), systolic blood pressure, diastolic 
blood pressure, and heart rate (bpm). Also, the type of MI, 
target vessel, and chest pain time were recorded in all patients. 
Blood samples and echocardiography 
In all patients, antecubital venous blood samples for labora-
tory analysis were drawn upon admission into the emergency 
room. Biochemical markers were measured with an auto-
mated chemistry analyser. 
Transthoracic echocardiography was performed for each 
patient immediately after primary PCI in a coronary intensive 
care unit (Vivid 7® GE Medical System, Horten, Norway). 
Ejection fraction was determined using the Simpson’s method, 
according to the recommendations of the American Society 
of Echocardiography [9].
Coronary angiography (TIMI flow grade) 
All patients underwent selective coronary angiography us-
ing the Judkins technique. Primary PCI procedures were 
performed with standard femoral approach with a 7-French 
guiding catheter. To achieve maximal dilatation each coronary 
angiogram was preceded by intracoronary injection of 100 µg 
nitroglycerine. TIMI flow grade was assessed in consensus by 
three experienced interventional cardiologists who did not 
have knowledge of the clinical and laboratory data. Pre-PCI 
TIMI flow grade was documented for each patient. Patients 
were divided into two groups based on the TIMI flow grade [2]: 
the impaired IRA patency group was defined as TIMI grade 0 
and 1 flow (non-patent IRA group), and the patent IRA group 
was defined as TIMI 2 and 3 flow before intervention [10].
Statistical analysis 
All analyses were conducted using SPSS 17.0 (SPSS for Win-
dows 11.5, Chicago, IL). Normally distributed continuous 
variables were expressed as mean ± standard deviation, 
non-normally distributed variables were expressed as me-
dian (minimum–maximum), and categorical variables were 
expressed as percentages. Comparisons of categorical and 
continuous variables between the two groups were performed 
using the c2 test and independent samples t-test, respectively. 
A p-value of < 0.05 was considered significant for univariate 
analysis. Binary logistic regression analysis was used to deter-
mine the independent predictors of IRA patency. Variables 
with a p value lower than 0.25 in univariate analysis were 
entered in multivariate analysis. 
RESULTS
Univariate analysis 
Clinical characteristics, echocardiographic and laboratory 
findings of patients were shown in Table 1. Patients in the 
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patent IRA group were more likely to be male and have 
diabetes, hypertension, and hyperlipidaemia. Smoking 
habit was more frequent in the non-patent IRA group. Tro-
ponin and creatinine kinase MB levels were higher in the 
non-patent IRA group. Left ventricular ejection fraction was 
higher in the patent IRA group than in the non-patent IRA 
group (p < 0.05, for all; Table 1). 
Medications used before MI are shown and compared 
between groups in Table 2. Pretreatment with statin was higher 
in the patent IRA group compared with the non-patent IRA 
group (138 [71.9%] vs. 79 [10.6%], p < 0.001). Atorvastatin 
and rosuvastatin usage was also higher in the patent IRA group 
compared with the non-patent IRA group (p < 0.001 for 
both). Statin usage duration was similar between groups 
(2.02 ± 1.04 vs. 1.97 ± 1.01 years, p = 0.728). Beta-blocker 
and oral antidiabetic drugs  were used more frequently in the 
patent IRA group (p < 0.05, for all). 
Our data were collected from 465 (49.6%) patients with 
anterior STEMI, 398 (42.4%) with inferior STEMI, 63 (6.7%) 
with inferior posterior STEMI, and 12 (1.3%) with high lateral 
STEMI. The prevalence of inferior MI in the patent IRA group 
was larger than the non-patent IRA group (p = 0.05). Anterior 
MI in the patent IRA group occurred less frequently than in the 
non-patent IRA group (p = 0.009). Also, the SYNTAX score 
was higher in the non-patent IRA group than in the patent IRA 
group (15.9 ± 6.8 vs. 12.1 ± 7.0, p < 0.001). The pain onset 
to first medical contact and door-to-balloon time were similar 
between groups (4.6 ± 5.1 vs. 5.1 ± 6.0 h, p = 0.254 and 
32.6 ± 6.9 vs. 31.9 ± 7.4 min, p = 0.281; Table 3). 
Multivariate logistic regression analysis 
Infarct-related artery patency was independently associa-
ted with body mass index (odds ratio [OR] 1.090, 95% 
confidence interval [CI] 1.011–1.175, p = 0.025), pre-
vious chronic statin use (OR 0.067, 95% CI 0.046–0.099, 
p < 0.001), and SYNTAX score (OR 0.919, 95% CI 0.892– 
–0.947, p < 0.001) in multivariate logistic regression analy-
sis (Table 4).
Table 1. Comparison of baseline characteristics, risk factors, and laboratory findings between the groups
Variables Patent IRA group (n = 192) Non-patent IRA group (n = 746) p
Baseline characteristics:
Age [years] 58.6 ± 12.5 58.4 ± 11.9 0.842
Gender (male) 129 (67.2%) 553 (74.1%) 0.035
BMI [kg/m2] 26.6 ± 2.5 26.2 ± 2.6 0.054
Systolic BP [mmHg] 118.8 ± 16.7 119.6 ± 20.9 0.631
Diastolic BP [mmHg] 73.0 ± 13.7 71.5 ± 11.4 0.178
Heart rate [bpm] 89.6 ± 13.1 90.5 ± 14.8 0.854
Ejection fraction [%] 48.0 ± 9.8 45.0 ± 9.3 < 0.001
Risk factors:
Diabetes 66 (34.4%) 207 (27.7%) 0.044
Hypertension 85 (44.3%) 279 (37.4%) 0.049
Hyperlipidaemia 138 (71.9%) 124 (16.6%) < 0.001
Smoking 64 (33.3%) 308 (41.3%) 0.026
Laboratory findings:
Glucose [mg/dL] 150.2 ± 83.8 159.1 ± 86.5 0.196
Total cholesterol [mg/dL] 192.3 ± 45.3 189.2 ± 45.9 0.648
Triglyceride [mg/dL] 158.2 ± 102.7 145.1 ± 112.8 0.157
HDL-C [mg/dL] 37.9 ± 9.6 38.1 ± 9.0 0.860
LDL-C [mg/dL] 122.8 ± 40.3 122.1 ± 36.2 0.808
Creatinine [mg/dL] 0.95 ± 0.48 1.05 ± 0.68 0.057
Haemoglobin [g/dL] 13.2 ± 1.8 13.5 ± 2.0 0.071
White blood cell count [103/µL] 9.9 ± 4.0 10.2 ± 4.1 0.256
CK-MB [ng/mL] 29.70 (0.80–300) 49.70 (0.50–500) 0.001
Troponin [ng/mL] 6.76 (0.01–100) 14.17 (0.01–100) < 0.001
Data are shown as mean ± standard deviation, number (percentage) or median (minimum–maximum). Students t test, Kruskal Wallis and c2 tests 
were used. BMI — body mass index; BP — blood pressure; CK-MB — creatine kinase muscle and brain; HDL-C — high-density lipoprotein cholesterol; 
LDL-C — low-density lipoprotein cholesterol; IRA — infarct-related artery
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Table 2. Comparison of medications used before primary percutaneous coronary intervention between groups
Variables Patent IRA group (n = 192) Non-patent IRA group (n = 746) p
Previous medications:
Statin use (total) 138 (71.9%) 110 (14.7%) < 0.001
Atorvastatin use 95 (49.5%) 79 (10.6%) < 0.001
Atorvastatin 10 mg 55 (28.6%) 36 (4.8%)
Atorvastatin 20 mg 23 (11.9%) 18 (2.4%)
Atorvastatin 40 mg 12 (6.2%) 14 (1.8%)
Atorvastatin 80 mg 5 (2.6%) 11 (1.4%)
Rosuvastatin use 43 (22.4%) 31 (4.2%) < 0.001
Rosuvastatin 10 mg 31 (16.1%) 24 (3.2%)
Rosuvastatin 20 mg 12 (6.2%) 7 (0.9%)
Statin usage duration [years]: 2.02 ± 1.04 1.97 ± 1.01 0.728
ACE-I use 50 (26%) 168 (22.5%) 0.175
ARB use 35 (18.2%) 137 (18.4%) 0.530
Beta-blocker use 27 (14.1%) 62 (8.3%) 0.013
ASA use 40 (20.8%) 124 (16.6%) 0.104
OAD use 79 (41.1%) 207 (27.7%) <0.001
Data are shown as mean ± standard deviation or number (percentage). c2 test was used. ACE-I — angiotensin converting enzyme inhibitor; ARB — 
angiotensin receptor blocker; ASA — acetylsalicylic acid; IRA — infarct-related artery; OAD — oral antidiabetic drug
Table 3. Comparison of angiographic findings between groups
Variables Patent IRA group (n = 192) Non-patent IRA group (n = 746) p
Angiographic findings:
SYNTAX score 12.1 ± 7.0 15.9 ± 6.8 < 0.001
LMCA involvement 1 (0.5%) 13 (1.7%) 0.184
LAD involvement 79 (41.1%) 372 (49.9%) 0.019
RCA involvement 78 (40.6%) 269 (36.1%) 0.139
CX involvement 22 (11.4 %) 71 (9.5%) 0.274
Other (diagonal, ramus) involvement 12 (6.2%) 21 (2.8%) 0.124
Type of infarct:
Anterior MI 80 (41.7%) 385 (51.6%) 0.009
Inferior MI 92 (47.9%) 306 (41.0%) 0.051
High lateral MI 5 (2.6%) 7 (0.9%) 0.078
Inferior posterior MI 15 (7.8%) 48 (6.4%) 0.347
Pain onset to FMC time [h] 4.6 ± 5.1 5.1 ± 6.0 0.254
Door-to-balloon time [min] 32.62 ± 6.97 31.97 ± 7.47 0.281
Killip class 2–4 6 (3.1%) 68 (9.1%) 0.03
Cardiogenic shock 2 (1.04%) 9 (1.2%) 0.449
Data are shown as mean ± standard deviation or number (percentage). c2 and Kruskal Wallis tests were used. CX — circumflex artery; FMC — 
first medical contact; IRA — infarct-related artery; LAD — left anterior descending artery; LMCA — left main coronary artery, MI — myocardial 
infarction; RCA — right coronary artery
DISCUSSION 
The present study evaluated the impact of previous treat-
ment with statins and other treatments such as ACE inhibitor, 
beta-blocker, and oral antidiabetic drug use on pre-PCI IRA 
patency of patients with STEMI treated with primary PCI. 
Chronic pretreatment of patients with acute coronary 
syndromes with statins has been associated with a decrease 
in risk of cardiovascular events, including mortality and re-
current MI [4, 11, 12]. Statin pre-treatment protects against 
myocardial damage during coronary intervention [13]. 
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Also, statin pre-treatment reduces the rate of MI after PCI 
[14]. These beneficial effects of statins are associated with 
anti-inflammatory  as well as plaque-stabilising effects [15].  
In previous studies it was shown that pretreatment 
with statins decreased the risk of no reflow phenomenon 
[7, 8]. Prior statin use has been shown to preserve coronary 
microvascular integrity during cardiac stress in experimental 
hypercholesterolaemia, independent of lipid lowering [16]. In 
addition, chronic administration of statins has cardioprotec-
tive effects in ischaemia/reperfusion injury despite unaltered 
cholesterol levels [17]. Celik et al. [7] reported that prior statin 
use may improve coronary blood flow after primary PCI in pa-
tients with STEMI. In another study, Iwakura et al. [8] enrolled 
293 consecutive patients with STEMI undergoing successful 
primary PCI and found that patients receiving chronic statin 
treatment before admission had lower incidence of no-reflow 
than those without it (9.1% and 34.6%). Several mechanisms 
have been proposed for this beneficial effect. Pre-PCI chronic 
statin treatment may reduce embolic events during coronary 
intervention by decreasing lipid content and increasing the 
thickness of the fibrous cap of the atherosclerotic plaque [15]. 
The mechanism for achieving better myocardial perfusion may 
be related to inhibitory effects on platelets and blood coagula-
tion, improvement in endothelial function,  plaque-stabilising 
effects, and reduction in inflammatory response by statins [18, 
19]. In patients with acute coronary syndrome, statins reduce 
monocyte adhesion molecules and serum P-selectin levels 
and inhibit the adhesion of leukocytes to the endothelium. 
These changes result in reduced capillary obstruction caused 
by platelet and leukocyte aggregates, which in turn results in 
preserved coronary microvascular permeability and reduced 
intracellular oedema after reperfusion. Statins reduce the 
expression of monocyte adhesion molecules, inhibit the ad-
hesion of leukocyte to endothelia cells [20], and lower serum 
P-selectin levels in patients with acute coronary syndrome [21]. 
Statin treatment preserves the coronary microvascular per-
meability, which might lead to the reduction of intracellular 
oedema after reperfusion [16]. Statins have beneficial effects 
on endothelial function and nitric oxide (NO) production, 
independent of changes in serum LDL levels [6, 22], which 
might be responsible for the prevention of no-reflow phe-
nomenon in acute coronary syndromes [8].
Present study showed that pretreatment with statin 
was associated with a patent IRA upon presentation in 
STEMI-patients. Also, in the present study, the relationship 
between pretreatment statin use and pre-PCI IRA patency 
was independent of the LDL-C levels. To our knowledge, 
there are not enough data regarding the effects of prior 
statin use on pre-PCI patency of IRA in patients with STEMI 
undergoing primary PCI. In our study, we found that patients 
with normal flow in IRA had higher incidence of prior statin 
use. In the present study, the positive impact on IRA patency 
was independent of the type of statins. The “pleiotropic” 
effects of statins could contribute to pre-PCI IRA patency as 
well as lower risk of no-reflow in patients with STEMI. The 
beneficial effects related with statin use, such as inhibitory 
effects on platelets and blood coagulation, improvement in 
endothelial function, NO production,  plaque-stabilising ef-
fects and reduction in inflammatory response, may be respon-
sible mechanisms for pre-PCI IRA patency [6, 18, 19]. Also, 
statins upregulate endothelial NO synthase activity [6, 23], 
inhibit platelet CD40 ligand mediated thrombin generation 
[24], and increase fibrous cap thickness and plaque stability 
[19]. In a study conducted on patients with the first STEMI, 
infarct-related coronary plaques were assessed with intravas-
cular ultrasound and statin treatment before the onset of MI 
was associated with coronary plaque morphology with less 
necrotic core and greater fibrous and fibrofatty components 
at the culprit lesion in the IRA [25]. In a study by Robinson et 
al. [10], as the number of medications including statins, ACE 
inhibitors, acetylsalicylic acid, and beta-blockers increased, 
the likelihood of IRA patency increased. However, that study 
did not investigate the separate effects of drugs on pre-PCI IRA 
patency. In the present study, the frequency of pretreatment 
with beta-blocker was higher in the IRA patency group com-
pared with the non-patent IRA group. The IRA patency was 
not independently associated with previous beta-blocker use. 
Similarly, although the frequency of pretreatment with oral 
anti-diabetic drug use was higher in the pre-PCI patent IRA 
group, it was not related to pre-PCI IRA patency in logistic re-
gression analysis. Finally, only statin usage was independently 
associated with pre-PCI IRA patency in the present study.
Limitations of the study
Subjects participating in our study were enrolled prospectively, 
and statins were used before enrolment, which makes our 
study a retrospective cohort study in terms of the cause-effect 
relationship. Therefore, our results are subject to the weak-
nesses of retrospective design. Prospective enrolment in our 
study helps to avoid significant bias.
CONCLUSIONS
In our study, chronic statin therapy before the onset of acute 
MI was independently associated with IRA patency. Therefore, 
Table 4. Multivariate relationships of infarct-related artery patency
Variables B 95% CI p 
Body mass index [kg/m2] 1.090 1.011–1.175 0.025
SYNTAX score 0.919 0.892–0.947 < 0.001
Statin use 0.067 0.046–0.099 < 0.001
R2 = 0.391. Binary logistic regression test was used. CI — confidence 
interval
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statin therapy in patients free from cardiovascular disease may 
improve clinical outcomes of the first STEMI by improving 
pre-interventional IRA patency. 
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